Parkinson Disease, Secondary
"Parkinson Disease, Secondary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
Descriptor ID |
D010302
|
MeSH Number(s) |
C10.228.140.079.862.800 C10.228.662.600.700
|
Concept/Terms |
Parkinson Disease, Secondary- Parkinson Disease, Secondary
- Secondary Parkinson Disease
- Symptomatic Parkinson Disease
- Parkinsonism, Symptomatic
- Symptomatic Parkinsonism
- Secondary Parkinsonism
- Parkinson Disease, Symptomatic
- Parkinsonism, Secondary
|
Below are MeSH descriptors whose meaning is more general than "Parkinson Disease, Secondary".
Below are MeSH descriptors whose meaning is more specific than "Parkinson Disease, Secondary".
This graph shows the total number of publications written about "Parkinson Disease, Secondary" by people in this website by year, and whether "Parkinson Disease, Secondary" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2008 | 1 | 0 | 1 |
2011 | 1 | 0 | 1 |
2014 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Parkinson Disease, Secondary" by people in Profiles.
-
Methamphetamine self-administration results in persistent dopaminergic pathology: implications for Parkinson's disease risk and reward-seeking. Eur J Neurosci. 2014 Aug; 40(4):2707-14.
-
Methamphetamine-induced vascular changes lead to striatal hypoxia and dopamine reduction. Neuroreport. 2011 Dec 07; 22(17):923-8.
-
Fos expression following activation of the ventral pallidum in normal rats and in a model of Parkinson's Disease: implications for limbic system and basal ganglia interactions. Brain Struct Funct. 2008 Sep; 213(1-2):197-213.
-
Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol Dis. 2007 Apr; 26(1):56-65.
-
Proteasome inhibition and Parkinson's disease modeling. Ann Neurol. 2006 Aug; 60(2):260-4.
-
Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann Neurol. 2006 Aug; 60(2):264-8.